
Opinion|Videos|March 4, 2025
Neurological Conditions and Bladder Dysfunction
Author(s)Tamara Kaplan, MD
Panelist discusses how neurogenic bladder in neurological conditions manifests distinctly based on lesion location. Patients with multiple sclerosis typically experience detrusor overactivity and sphincter dyssynergia, leading to urgency and retention. Parkinson disease commonly presents with overactive bladder symptoms and nocturia due to impaired basal ganglia control. Cauda equina syndrome and lumbar disc herniation often result in detrusor areflexia and decreased sensation, causing retention and overflow incontinence.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please discuss how neurogenic bladder can manifest in patients with neurologic conditions.
- Multiple sclerosis
- Parkinson disease
- Cauda equina syndrome and herniated lumbar discs
Advertisement
Related to this article

Xenon Pharmaceuticals submitted an FDA New Drug Application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy.

The CHMP recommended approval of gefurulimab (Klygefa), a weekly self-administered C5 inhibitor, for AChR-antibody-positive generalized myasthenia gravis in the EU.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease biomarkers!

A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex.

The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Gefurulimab Recommended for EU Approval in Generalized Myasthenia Gravis
2
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
3
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures
4
Episode 175: Advancing the Ways of Treating Cluster Headache
5




